Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global Secukinumab market was valued at approximately USD 4.5 billion in 2024. The market is projected to grow from USD 4.9 billion in 2025 to reach USD 7.8 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.8% during the forecast period.
Secukinumab is a fully human monoclonal antibody that selectively targets and neutralizes interleukin-17A (IL-17A), a key cytokine involved in inflammatory processes. It was the first IL-17 inhibitor approved by the US Food and Drug Administration (FDA) for the treatment of moderate to severe plaque psoriasis, and its indications have since expanded to include psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. The drug is commercially known as Cosentyx.
The market growth is primarily driven by the high and rising global prevalence of immune-mediated inflammatory diseases, coupled with the strong clinical efficacy profile of Secukinumab. However, the market faces challenges from biosimilar competition as key patents begin to expire in major markets post-2025, which is expected to impact the branded product's revenue. Furthermore, the robust pipeline of competing biologic therapies and the high cost of treatment are significant factors influencing market dynamics. The U.S. remains the dominant market, accounting for over half of global sales, while the Asia-Pacific region is anticipated to witness the fastest growth due to improving healthcare access and rising diagnostic rates.
Rising Prevalence of Immune-Mediated Inflammatory Diseases
The global incidence of chronic inflammatory conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis continues to climb, creating a sustained and growing patient population requiring long-term biologic therapy. Secukinumab, as a first-line biologic option, is positioned to capture a significant share of this expanding market. The high efficacy and rapid onset of action demonstrated in clinical trials support its robust adoption.
Superior Efficacy and Favorable Safety Profile
Clinical data consistently shows that secukinumab achieves higher rates of skin clearance (PASI 90 and PASI 100 scores) compared to older anti-TNF agents and other biologics in its class. This superior efficacy profile, combined with a well-characterized and manageable safety profile, drives its preference among dermatologists and rheumatologists, making it a cornerstone of treatment protocols.
The IL-17A inhibition pathway targeted by secukinumab has proven to be highly effective, leading to its inclusion in major international treatment guidelines.
Furthermore, continuous real-world evidence and long-term extension studies reinforce the drug's durability of response and safety, providing clinicians with the confidence to prescribe it for extended periods, thereby ensuring recurring revenue streams.
MARKET CHALLENGES
Intense Competition and Pricing Pressures
The market for psoriasis and psoriatic arthritis treatments is highly competitive, with the presence of numerous established biologics and the emergence of biosimilars for older drugs. This creates significant pricing pressure and necessitates aggressive discounting and rebate strategies to secure formulary placements, which can erode profit margins.
Other Challenges
Patent Expiration and Biosimilar Threats
The eventual loss of patent exclusivity for secukinumab in key markets presents a long-term challenge. The anticipated entry of biosimilar versions will intensify price competition and challenge the brand's market share, requiring strategic lifecycle management to defend its position.
Adherence and Injection Fatigue
Despite its efficacy, some patients experience injection fatigue or discomfort with the self-administered delivery system. This can lead to non-adherence, impacting treatment outcomes and potentially affecting the drug's perceived value in a crowded market.
High Cost of Biologic Therapies
The significant cost of secukinumab remains a primary barrier to access, particularly in cost-conscious healthcare systems and emerging markets. Reimbursement hurdles and restrictive payer policies can limit patient access, slowing down market penetration rates even in regions with high disease burden.
Risk of Serious Infections and Adverse Events
As with all immunomodulatory agents, secukinumab carries a risk of serious infections, including an increased susceptibility to candidiasis. While the overall risk is considered manageable, it necessitates careful patient screening and monitoring, which can be a deterrent for both clinicians and patients considering treatment initiation.
Expansion into New Geographic Markets
There is significant potential for growth in emerging economies across Asia-Pacific and Latin America, where improving healthcare infrastructure, rising diagnosis rates, and increasing healthcare expenditure are creating new access points for advanced biologic therapies like secukinumab.
Exploration of New Therapeutic Indications
Ongoing clinical research is investigating the efficacy of secukinumab in other immune-mediated conditions beyond its current approvals. Positive results in new indications such as hidradenitis suppurativa or non-radiographic axial spondyloarthritis could substantially expand the eligible patient population and drive future revenue growth.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Patent formulations hold a dominant leadership position due to their established efficacy for approved indications like plaque psoriasis and the significant R&D investment and strong brand recognition associated with the innovator product. The intellectual property protection provides a period of market exclusivity, fostering high confidence among prescribing physicians. Meanwhile, the Generic segment represents a critical future growth avenue, as the eventual expiration of patents is expected to increase market accessibility and introduce competitive pricing pressures, making the treatment available to a broader patient population. |
| By Application |
|
Pharmaceutical applications are the unequivocal leader, as Secukinumab is primarily developed and certified as a biologic drug for therapeutic use in autoimmune diseases. This segment's dominance is underpinned by robust clinical validation, established manufacturing protocols adhering to Good Manufacturing Practice (GMP), and widespread distribution through healthcare channels. The Research & Development segment is also highly significant, driving innovation through clinical trials exploring new indications and combination therapies, which continually expands the potential patient base and reinforces the drug's long-term therapeutic value. |
| By End User |
|
Hospitals serve as the preeminent end-user segment, as they are the primary centers for administering specialized biologic treatments like Secukinumab, which often require supervised infusion or injection. Their comprehensive infrastructure for handling complex therapies and managing patient care solidifies their leading role. Specialty Clinics, particularly in dermatology and rheumatology, are also crucial end-users, offering targeted and accessible care for chronic conditions. Research Institutes contribute significantly by utilizing the drug in clinical studies, which is vital for validating new treatment protocols and expanding approved uses. |
| By Distribution Channel |
|
Hospital Pharmacies are the leading distribution channel, directly aligned with the hospital end-user segment, ensuring seamless supply chain management for in-patient and out-patient administration of this specialized medication. Retail Pharmacies play an important role in distributing the drug for patient self-administration after initial training, enhancing convenience for long-term therapy. The Online Pharmacies segment is an emerging channel, gaining traction by offering accessibility and discreet services, though it faces stricter regulatory scrutiny for distributing prescription biologics. |
| By Therapeutic Area |
|
Plaque Psoriasis represents the foundational and leading therapeutic area for Secukinumab, as it was the first indication for which the drug received approval, establishing its clinical profile and driving initial market adoption. The strong efficacy data in this area continues to be a major growth driver. Psoriatic Arthritis and Ankylosing Spondylitis are other significant approved indications that have substantially expanded the drug's utility and patient reach, demonstrating its versatility in treating interrelated autoimmune conditions and creating a broad therapeutic footprint. |
A Market Characterized by a Mix of Innovator and Generic API Suppliers
The global Secukinumab market's competitive landscape is dominated by the originator, Novartis AG, which holds the patent for the blockbuster drug Cosentyx. As a first-in-class IL-17A inhibitor, Cosentyx commands a leading position in the biologic therapeutics market for psoriasis, psoriatic arthritis, and ankylosing spondylitis, driving the majority of the market's revenue. However, the competitive structure is evolving with the entry of active pharmaceutical ingredient (API) manufacturers preparing for the patent expiration. The global market features a highly fragmented supplier base, particularly for the generic and research-grade segments of the Secukinumab supply chain, with numerous specialized biotechnology and chemical companies vying for position.
Beyond the innovator, the competitive field includes a significant number of chemical and biotechnology companies, primarily based in China, that are developing and supplying Secukinumab for research purposes and future generic drug production. These niche players, such as Hubei Widely Chemical Technology and Shanghai Biochempartner, focus on securing a share in the high-growth potential generic market. Their strategies often involve scaling up synthesis capabilities and ensuring regulatory compliance to capitalize on the upcoming patent cliff. Competition among these suppliers is intensifying based on price, purity, production capacity, and reliability of supply.
List of Key Secukinumab Companies ProfiledNovartis AG
Changzhou Chenhong Biotechnology
DC Chemicals
Huatesheng Biotechnology
Hubei Guangao Biotechnology
Hubei Kele Fine Chemical
Hubei Xingcheng Biotechnology
Hubei Zhongshan Medical Technology
Jiangxi Ruiweier Biotechnology
Nantong Hi-Future Biotechnology
Shanghai Minkai Biotechnology
The global Secukinumab market is on a significant growth trajectory, projected to expand at a compound annual growth rate from 2024 to 2032. This growth is largely driven by the robust demand for effective biologic treatments for immune-mediated inflammatory diseases. As a fully human monoclonal antibody that selectively neutralizes interleukin-17A, Secukinumab has established a strong position in the treatment landscape for moderate to severe plaque psoriasis, following its initial approval by the US Food and Drug Administration. The increasing global prevalence of psoriasis and psoriatic arthritis, coupled with growing patient and physician acceptance of advanced biologic therapies, continues to fuel market expansion. The market's valuation, reaching millions of US dollars, underscores the significant commercial success and widespread adoption of this targeted therapy.
Other TrendsDominance of Patent-Protected Product
The market is currently segmented into patent and generic types, with the patent segment expected to reach a multi-million dollar valuation by 2032, demonstrating a significant compound annual growth rate over the forecast period. This dominance of the patent-protected product reflects the ongoing market exclusivity and the high barrier to entry for biosimilar competition. The sustained revenue generation from the patented formulation is a key trend, highlighting the continued innovation and brand loyalty associated with the originator product before the anticipated introduction of biosimilars in future years.
Regional Market Dynamics and Competitive LandscapeGeographically, the market exhibits distinct dynamics. The United States market is a major contributor, with an estimated size in the millions for 2024, driven by high treatment adoption rates and favorable reimbursement structures. Meanwhile, the Chinese market is projected to grow substantially, aiming to reach a multi-million dollar valuation, indicating a rapidly expanding pharmaceutical sector and increasing access to innovative biologic drugs. The competitive landscape is characterized by a concentrated group of key global manufacturers, including Carbosynth, TargetMol Chemicals, and several Chinese biotechnology firms. In 2024, the top five players collectively held a significant share of the global revenue, indicating a market with established leaders. This concentration points towards trends of strategic manufacturing, supply chain control, and technological expertise being critical for maintaining a competitive edge.
Regional Analysis: Secukinumab MarketEurope
Europe represents a major market for Secukinumab, characterized by strong healthcare systems and centralized purchasing mechanisms. Market access varies across countries, with Germany and the UK being key adopters due to positive health technology assessment outcomes. Price negotiations with national health authorities are a critical factor influencing uptake. The market faces pressure from cost containment policies and the presence of biosimilars for other biologics, creating a more cost-conscious environment. Despite this, Secukinumab maintains a strong position based on its clinical data and physician trust, particularly for patients who have failed other therapies. Regional guidelines often recommend it as an effective option for moderate-to-severe plaque psoriasis.
Asia-Pacific
The Asia-Pacific region is the fastest-growing market for Secukinumab, fueled by increasing disease awareness, improving healthcare infrastructure, and rising disposable incomes. Japan and Australia are the most established markets, with early approval and reimbursement. Growth in China and South Korea is accelerating as regulatory pathways streamline and local clinical data accumulates. Challenges include price sensitivity and the need for education among a broader base of physicians. The vast patient population presents a significant long-term opportunity, with market penetration deepening beyond major metropolitan areas. Cultural attitudes towards chronic skin conditions are also evolving, driving demand for advanced treatments.
South America
The South American market for Secukinumab is emerging and varies significantly by country, with Brazil and Argentina being the primary markets. Access is often limited to urban centers and private healthcare sectors, with public health system inclusion being a slower process. Economic volatility and currency fluctuations can impact pricing and affordability. Despite these challenges, there is growing recognition of the clinical benefits among specialists. Market growth is primarily driven by the private sector and a growing middle class seeking advanced medical care. Partnerships with local distributors are key to navigating the diverse regulatory landscapes.
Middle East & Africa
This region exhibits a highly diverse and nascent market for Secukinumab. The Gulf Cooperation Council countries, particularly Saudi Arabia and the UAE, lead adoption due to higher healthcare spending and well-developed private hospitals. Reimbursement is often available for expatriates and citizens with premium insurance. In other parts of the region, access is limited and often out-of-pocket, restricting use to affluent patients. Market development focuses on physician education and navigating complex regulatory and importation processes. Long-term growth potential is significant but hinges on economic development and healthcare infrastructure improvements across the continent.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> Global Secukinumab market was valued at USD 4.5 billion in 2024 and is projected to reach USD 7.8 billion by 2032.
Which key companies operate in Global Secukinumab Market?
-> Key players include Carbosynth, TargetMol Chemicals, Changzhou Chenhong Biotechnology, DC Chemicals, and Huatesheng Biotechnology, among others.
-> Key growth drivers include rising prevalence of immune-mediated inflammatory diseases and strong clinical efficacy profile.
-> U.S. remains the dominant market, while Asia-Pacific is anticipated to witness the fastest growth.
-> Emerging trends include biosimilar competition as key patents expire post-2025 and new biologic therapies.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates